Vitamin E is a dietary compound that has strong antioxidant properties. Vitamin E has been shown to act on some toxic chemicals that may contribute to the damage seen in AD. Many laboratory, animal and epidemiological studies have pointed towards a possible beneficial role for vitamin E in the prevention and treatment of AD. However, to date very limited evidence exists in humans to support the routine use of vitamin E. Further, in recent years evidence has come to light implicating vitamin E with potentially serious side effects and even increased mortality. In this review three studies were identified and these demonstrated no or limited benefit for vitamin E in MCI and AD. Therefore, vitamin E should not be used in the treatment of MCI or AD. More trials are still needed but these should include different forms of vitamin E.
Vitamin E should not be used for the treatment of mild cognitive impairment (MCI) and Alzheimer's dementia (AD)
14 November 2012
This record should be cited as:
Farina N, Isaac MGEKN, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD002854. DOI: 10.1002/14651858.CD002854.pub3
Assessed as up to date:
25 June 2012
More like this
- No evidence that folic acid with or without vitamin B12 improves cognitive function of unselected elderly people with or without dementia. Long-term supplementation may benefit cognitive function of healthy older people with high homocysteine levels
- No evidence of benefit from vitamin B6 supplementation on mood or cognition of older people with normal vitamin B6 status or with vitamin B6 deficiency
- Procaine is a controversial substance that has been used for "antiageing" effects including cognitive improvement for more than 50 years
- Melatonin treatment may be effective for the treatment of dementia-related behavior disturbances
- There is currently insufficient evidence of the effects of Huperzine A for Alzheimer's disease (AD).